Chemistry le Biology ea Orexin Signaling (2010)

Mol Biosyst. Sengoloa se ngotsoeng; e fumaneha ho PMC 2012 Jun 20.

E hatisitsoe ka mokhoa o qetelle o hlophisitsoeng e le:

PMCID: PMC3379554

NIHMSID: NIHMS280225

Moetso oa khatiso oa ho qetela oa mohatisi o fumaneha ho Mol Biosyst

Sheba lihlooho tse ling ho PMC hore Qotsa sehlooho se hatisitsoeng.

Eya ho:

inahaneloang

Li-orexins ke li-neurohormones tseo, ka kopanelo le li-receptor tsa bona tsa kelello, li laolang lits'ebetso tse 'maloa tsa bohlokoa tsa' mele, ho kenyelletsa ho fepa, ho robala, ho batla moputso le homeostasis ea matla. Li-receptor tsa orexin li sa tsoa hlaha e le lipheo tsa bohlokoa tsa lithethefatsi. Tlhahlobo ena e fana ka kakaretso ea nts'etsopele ea morao-rao ea ho phetola biology ea orexin signaling le boiteko ba ho sebelisa orexin signaling pharmacologically.

Li-orexins (tseo hape li bitsoang li-hypocretins) ke li-neuropeptides tse ileng tsa fumanoa ka lekhetlo la pele ho 1998 ke lihlopha tse peli tse ikemetseng tsa lipatlisiso1, 2. Li-Orexins A (33 amino acid) le B (28 amino acid) li tsoa polypeptide e le 'ngoe ea pro-orexin polypeptide3. Ba buella liketso tsa bona ka ho sebelisana le GPCR tse peli tse amanang haufi tse bitsoang Orexin Receptor 1 le 2 (OxR1 le OxR2). OxR1 e kopanya Orexin A e nang le kholiseho e phahameng ea 100 e fetang Orexin B athe OxR2 e tlama li-peptide ka bobeli ka mokhoa o tšoanang oa tumellano e tšoanang. Li-orexins li hlahisoa ke li-neuron tse ikhethang ho hypothalamus, tse sebetsang libakeng tse fapaneng tsa kelello4, 5.

Joalokaha ho tla hlahlojoa ka bokhutšoanyane ka tlase, lithuto tsa 'mele lilemong tse leshome tse fetileng li kentse letsoho ho supa ha orexin e le karolo ea mantlha mererong e fapaneng ea tlhaho ea tlhaho, ho kenyelletsa ho fepa, homeostasis ea matla, mekhahlelo ea ho robala / ho tsosa, ho lemalla le ho batla moputso, har'a tse ling6. Ho na le bopaki bo hlakileng ba liphoso ho orexin ho supa hore o kenella ho batenya le lefu la tsoekere7, 8, narcolepsy9, 10, letsoalo la ho tšoenyeha11, bokhoba ba lithethefatsi12 le Lefu la Alzheimer's13. Kahoo, ho na le thahasello e kholo indastering ea lithethefatsi ho nts'etsopele ea metsoako e matla bakeng sa ho qhekella ha orexin signaling. Tsoelo-pele ea morao-rao kutloisisong le ho etseng pontso ea orexin e hlahlojoa mona.

Orexin e tšoaea ho hokahanya boroko le ho fepa

Karolo e utloisisoang hantle ka ho feta ea ho saena hoa orexin ke kopano ea ho fepa le ho robala. Boemo ba tlhahiso ea orexin ho hypothalamus bo amana hantle le boemo ba tsoekere ea mali 14. Ho supa ka Orexin, bonyane ka nako e khuts'oane, ho etsa hore motho a ikutloe a lapile ebile ho tsosa boitšoaro, mohlomong ka ho kenya li-neurons bokong tse hlahisang li-neuropeptide Y le lihomone tse amanang le eona. Ntle le moo, ho saena hoa orexin ke karolo ea mantlha ea ho hohela boemo ba ho phahama ha liphoofolo tse anyesang9, 15. Ka mantsoe a mang, orexin e fana ka taelo ea hore ha liphoofolo li lapile, le tsona lia tsoha, empa ha li khotsofetse, li ka robala. Sena se fana ka maikutlo a nepahetseng a hore liphoofolo li tla batla ho fepela lijo, li sa robala, ha li lapile.

Ho tlosoa hoa mofuta oa orexin kapa pentšele ka litoeba ho fella ka mokhoa o ts'oanang o ts'oanang le tlhalohanyo ea motho le katse ea bohlasoa, eo ho eona phoofolo e utloang ho robala ka mokhoa o sa lokelang ka nako ea eona e tloaelehileng, ho kenyelletsa le ho oela ka nako e sa tloaelehang.9. Ho joalo le ka lintja tse nang le mofuta oa phetoho o thusang inthaneteng ho mofuta oa li-OxR210. Boholo, le ha e se tsona kaofela, li-narcoleptics tsa motho, leha li sa na liphatsa tsa lefutso tse kenyeletsang orexin le li-receptor tsa eona, leha ho le joalo ha e na orexin e bonoang. Sena se nahanoa hore ke ka lebaka la tlhaselo ea autoimmune ho li-neuron tse hlahisang orexin bokong16, 17. Leha ho le joalo, mokhoa ona oa autoimmune bakeng sa narcolepsy ea motho o ntse o ka netefatsoa mme ha ho letho le tsejoang ka mofuta oa karabelo ea autoimmune reaction.

Biology e tsebahalang ea orexin signaling ka hona e bolela esale pele hore li-agonists tse kenang bokong tsa OxR2 li lokela ho tsosa ho falla 'me li ka ba molemo bakeng sa kalafo ea narcolepsy. Yanagisawa le basebetsi-mmoho ba phatlalalitse bopaki ba liteko tsa mohopolo tse tšehetsang mohopolo ona18. Li bonts'itse hore ente e kenang ka kotloloho ea "orexin peptide" e kenang bokong ba litheko tse sa haellang tsa orexin e ile ea etsa hore a lule a falimehile. Ka lehlakoreng le leng, bahanyetsi ba orexin receptor ba ka sebelisoa ho phekola ho hloka boroko19, leha ho ka etsoa ka mokhoa oa ho sebelisa cataplexy, o bonoang liphoofolong le bathong ba nang le khaello e sa foleng ea orexin, ke taba e tšoenyang (vide infra).

Orexin e tšoaea boits'oaro bo botle ba boits'oaro

Insula ke sebaka sa boko se tsejoang ho nka karolo ho nts'etsopele ea litakatso le litakatso 'me ka kakaretso se nka karolo mekhoeng ea moputso20. Tšenyo e lebisang sebakeng sena sa boko e baka ho theoha ho hoholo hoa tšusumetso ea ba tsubang ho tsoela pele tloaelo ea bona21. Ho fapana le moo, ho ithiba ho tsubang ho tsuba ho tsebahala ka ho kenya ts'ebetsong bohlale22. Karolo e le 'ngoe ea boko e bonahala e ameha mekhoeng ea ho batla moputso e kenyelletsoang ho ekelletsa morphine, cocaine le joala. Li-neuron tse hlahisang Orexin li kenella ka hare ho sebaka sena sa boko mme ho supa ha orexin ho bapala karolo ea bohlokoa mekhoeng ena23-25. Mohlala, tsamaiso ea OxR1 antagonist khetha SB-334867 (bona Setšoantšo sa 5) ea fokotsehile haholo lits'oants'o tsa litoeba hore li itene ka nicotine12. Liphetho tse tšoanang li fumanoe bakeng sa likhomphutha tse ling tse lemalloang. Ho khahlisang ke hore lithutong tsa nicotine, pharmacological blockade of OxR1 ha ea ka ea hatella takatso ea lijo haholo, eo, hammoho le ho tsoha, ho nahanoang hore e buelloa haholo ke OxR2. Kahoo, tlhaiso-leseling ea pele ho tliliniki e litoebeng e fana ka maikutlo a hore litheko tsa ho khetha li-OxR1 e ka ba lithethefatsi tse khahlano le ho lemalla.

Setšoantšo sa 5 

Meaho ea bahanyetsi ba li-orexin receptor e hlahisitsoeng ke Glaxo Smith Kline (GSK) le Merck.

Ho supa ha Orexin morao tjena ho boetse ho bontšitsoe hore o kenya letsoho litlhaselong tsa ho tšoha le ho tšoenyeha11. U sebelisa mohlala oa litekanyetso moo litlhaselo tsa ts'abo li ts'oaroang ke kalafo ea phoofolo e sa ts'oaneng ka GABA synthesis inhibitor e lateloang ke kalafo e mpe ka sodium lactate, ho bontšitsoe hore SB-334867-Mediated blockade ea OxR1 kapa siRNA-Mediated silencing ea tlhahiso ea orexin ka matla e hatella tlhaselo ea tšabo mohlaleng ona. Ho feta moo, lithuto tsa batho tse tlas'a tlhaselo ea letsoalo li phahamisitse maemo a orexin mokhoeng oa bona oa "cerebrospinal fluid" (CSF) 11, e tsamaellanang le karolo ea ho supa ha orexin mathateng a matšoenyeho a batho.

Haufinyane tjena ho ile ha hlaha tlaleho e hokahanyang potoloho ea ho robala le ho tsoha le Lefu la Alzheimer's13. Haholo-holo ho ile ha bontšoa hore ho bokelloa ha amyloid beta, e leng lets'oao la lefu lena, ho tsamaisana le ho phaphama. Mohlala, ho haelloa ke boroko bo sa feleng ho eketsa maemo a beta ea amyloid ho CSF ​​ea phoofolo. Ho khahlisang, tsamaiso ea "orexin receptor antagonist SB-334867 e fokotsehile maemo a" interrediant "ena ea methapo. Kahoo, ho ka etsahala hore kalafo e nepahetseng ea kalafo le bahanyetsi ba OxR e ka ba kalafo e sebetsang ho liehisa nts'etsopele ea Lefu la Alzheimer's, haeba le fumanoe le sa le pele.

Orexin e tšoaea matla a homeostasis, ho nona haholo le lefu la tsoekere

Ho na le bopaki bo potelletseng ba hore ho supa li-orexin ho bohlokoa ho homeostasis ea matla. Mohlala, batho ba nang le letsoai ba haelloang ke orexin ba bonts'a lenane le phahameng la mmele ho feta batho ba narcoleptic ba maemong a tloaelehileng a orexin26. Ho koaleha liphatsa tsa lefutso ka li-neuron tsa orexin ho litoeba ho hlahisa liphoofolo tse motenya27 'me litoeba tsena li boetse li hanyetsa insulin e amanang le lilemo7. Liphetho tsena li bonahala li sa kopanyetseho ho seo khemisi e entsoeng ka eona ea orexin e bontšang ho hlakisa boitšoaro bo matla1. Sena se fana ka maikutlo a hore litlamorao tsa nako e khuts'oane le tsa nako e telele tsa lets'oao la orexin ho matla homeostasis li fapane.

Haufinyane, tikoloho ena ea biology ea orexin e hlakisitsoe ke tlhahlobo e ikhethang ea tlhahlobo ea hore orexin e hanyetsa ka matla botenya le ts'ebetso e ileng ea latela ea ho loants'oa ha insulin ka litoeba.8. Ho ile ha bonts'oa hore ho sa feleng ha polelo ea orexin gene kapa pharmacological induction ea orexin hoo e batlang e thibetse kholo ea botona le insulin ho hanyetsa litoeba li fepa lijo tse phahameng tsa mafura. Sena se bontšitsoe hore se bakoa haholo ke tšebeliso ea matla a eketsehileng, leha ho ne ho se na phetoho ho quotient ea phefumoloho, letšoao le sa tobang la ts'ebeliso ea nama ea nama ea methapo ea methapo le methapo. Ho hlohlelletsa ho sa feleng ha letšoao la orexin ho boetse ho fokotsa ts'ebeliso ea lijo. Liteko tse fapaneng tsa liphatsa tsa lefutso le tsa bongaka li bontšitse hore boholo ba phello ena bo kopantsoe le ho supa ka OxR2, eseng OxR1. Qetellong, sepheo se makatsang sa boithuto bona ke hore tšusumetso e sa feleng ea ho saena hoa orexin ha e na phello ho litoeba tse haelloang ke leptin. Liphoofolo tsena, ha li feptjoa lijo tse nang le mafura a mangata, li ne li ntse li le lingata ebile li le insulin esita le ha li phekoloa le agonist ea orexin. Kahoo, phello ea ts'ireletso ea orexin e bonahala e thehiloe ho ntlafatseng kutloisiso ea leptin. Phuputso ena e na le litlamorao tse hlakileng tsa kalafo kalafong ea botenya bo khothalletsoang ke ho ja le lefu la tsoekere.

Le ha thuto ena e hatisitse haholo ka OxR2 e le ea bohlokoa bakeng sa botenya bo sa tsitsang ba botenya, tse ling tsa litlamorao tsa OxR1-mediated li hlokometsoe8. Bangoli ba fumane hore liphatsa tsa lefutso tsa OxR1 feela e sirelelitsoe khahlanong le hyperglycemia e nang le mafura a mangata le hoja e se botenya. Sena se bonts'a hore orexin e supang ka OxR1 ke maemo a tloaelehileng a 'mele a orexin a bapala karolo ea lumelloang ho holiseng botsofali kapa mafura a mangata a amanang le insulin. Leha ho le joalo, boemong bo sa amaneng le 'mele oa orexin e tsitsitseng mabapi le polelo ka phetiso, bobeli bo sirelletsang ba OxR1- le OxR2 khahlano le nts'etsopele ea ho hanyetsa insulin lijong tse phahameng tsa mafura. Sephetho se rarahaneng sa sephetho mabapi le OxR1 se fana ka maikutlo a hore na receptor e bapala likarolo tse fapaneng tlasa maemo a tloaelehileng le a supraphysiological orexin expression, kapa hore receptor e lumellana le phello e fapaneng ea 'mele e ka ntlafatsang kapa ea hanyetsa nts'etsopele ea hyperinsulinemia le hore "ea hlolang" litlamorao tsena tsa tlholisano li fapana ho latela boemo ba orexin kapa nako le nako ea ho tšoaetsoa.

Ho kopanngoa ha phello ea orexin ho lets'oao la leptin hoa khahlisa ho mabapi le phuputso e 'ngoe e phatlalalitsoeng haufinyane moo ho fumanoeng hore maemo a holimo a leptin a lumella litoeba tsa lefu la tsoekere li haelloa ke insulin ka botlalo 28. Pejana, leptin e ne e tsejoa ho theola sekhahla sa tsoekere ea mali ka ho hlahisa litheko tse ling tsa "insulin" ea "mele" ho tsoa ho lefu la tsoekere la lefu la tsoekere ka lefu lena la insulin. 29. Leha ho le joalo, mohopolo oa hore leptin feela o ka pholosa liphoofolo tse haelloang ke insulin matšoao a lefu la tsoekere ha o e-so ka o hlahlojoa mme thabelo ena e ile ea makatsa haholo. Litla-morao tse tšoanang tse hlahisitsoeng ke kalafo e sa foleng ea liphoofolo tse nang le maemo a phahameng a orexin le leptin, hammoho le ho fumana hore orexin e bonahala e sebetsa ka ho ntlafatsa kutloisiso ea leptin, e lebisa motho ho ipotsa hore na lithuto tsena tse peli e ne e le mahlakore a fapaneng a chelete ea tšepe le hore tšusumetso ea Mokhoa orexin / leptin o bontšang litsela e ka ba kalafo e tšepisang bakeng sa lefu la tsoekere la mofuta oa II kapa lefu la tsoekere.

Na ho supa ka mokhoa orexin ho na le litlamorao?

Boholo ba litlamorao tsa ho saena hoa orexin tse hlalositsoeng ka holimo ho nahanoa hore li etsahala ho hypothalamus. Likarolo tsa orexin signaling, haeba li teng, kantle ho tsamaiso ea methapo lia likhang. Polelo ea li-orexin le li-receptor tsa tsona li fumanoe lithong tse fapaneng tsa pherekano, ho kenyelletsa le mala, makhopho, meno, adrenals, tishu ea adipose le mokhoa oa ho ikatisa. 30-33, empa bopaki bo sebetsang ba karolo ea ho saena hoa orexin ho potoloha e ka se fumanehe.

Phuputso ea morao-rao e bonts'itse hore ts'oaetso ea lisele tse hlalosang OxR1 sehlekehlekeng sa pancreatic e eketsehile ka li-streptozotocin (STZ) - e tsitsitseng hyperglycemia literekeng le ho sebeletsoa ka glucagon34. Ntle le moo, caspase e hlakisitsoeng-3 e kopantsoe le koae ka boomo le OxR1 lihlekehlekeng. Ka lehlakoreng le leng, liphoofolo li haelloa ke orexin, ka lehlakoreng le leng, li bonts'itse ho fokotsa hyperglycemia le mamello e ntle ea tsoekere ho feta liphoofolo tse hlaha. Liphetho tsena li fana ka maikutlo a hore orexin e supang ka OxR1 ka har'a manyeme e ka kenya letsoho ho beta cell apoptosis le nts'etsopele ea lefu la tsoekere ha a arabela kalafo ea STZ. Le ha khokahano e le boima, ho ka etsahala hore phello ena e ka hlalosa se hlokometsoeng ke Funato, et al., E boletsoeng ka holimo, hore ho tlosa liphatsa tsa lefutso ho OxR1 ho ne ho itšireletsa khahlanong le mafura a mangata a hlahisitsoeng ke hyperglycemia le hyperinsulinemia8.

Orexin e bontšang Cascade

Le ha ho supa matšoao a orexin ho ithutoe ka matla sethaleng sa 'mele, ho bile le boiteko bo fokolang bo fanoeng ho supa liketsahalo tsa bohlokoa tse bakiloeng ke ho tlama li-hormone tsa orexin ho li-receptors tsa bona. Hoa tsebahala hore ho tlama ha hormone ho receptor ea eona ho baka calcium, e kopantsoeng le ts'ebetso ea Erk 35. Li-receptors li boetse li tsamaisana le tsela ea phospholipase C (PLC) e tsamaisang mabenkele a calcium.

Tlhahlobo e phethahetseng ka botlalo ea mananeo a ho ngola liphatsa tsa lefutso a bakiloeng ke ho saena hoa orexin ho tlalehiloe ho 2007 36. Phuputso ena e sebelisitse polelo ea liphatsa tsa lefutso ea lefats'e ho tsebahatsa mefuta ea liphatsa tsa lefutso ho ea holimo kapa tlase ho lisele tsa HEK293 tse hlalosang hantle OxR1. Mefuta ea 260 e fumanoe e le taolo-tlase le 64 e tlase-e laoloang ke makhetlo a mabeli kapa ho feta ha e tekiloe lihora tse peli le tse nne kamora ho hlohlelletsoa ha orexin. Lingoloa tsa mofuta oa liphatsa tsa lefutso li bonts'itse hore halofo ea mofuta o hlophisitsoeng hantle haholo e kentse letsoho kholong ea lisele (30%) kapa metabolism (27%). Tlhahlobo ea tsela e sebelisang lenaneo la thekiso ea Ingenuity e khannile litsela tse 'maloa kaha li laoloa ke orexin signaling (Setšoantšo sa 1). Mokhoa o hlophisitsoeng oa canonical TGF-β / Smad / BMP, FGF, NF-kB, le litsela tse tšoaeang hypoxic e ne e le tsona tse hlahelletseng. Boithuto bona bo shebile ka kotloloho tseleng ea hypoxic, e neng e le "otla" ka mokhoa o sa tloaelehang thutong ena kaha lisele li ne li kengoe tlas'a maemo a tloaelehileng. Leha ho le joalo, mofuta oa phetisetso ea Hypoxia-Inducible Factor 1-α (HIF-1α), eo pele e neng e tsejoa e phahama ka karabelo ho hypoxia, mme mefuta e mengata ea eona e lebisitsoeng e ile ea susumetsoa haholo ke kalafo ea orexin. Liseleng tsa kankere ea hypoxic, moo ketso ea HIF-1cy e ithutoang hamolemo, e sebelisana le HIF-1β ho theha heterodimeric transcript factor (HIF-1) e tsamaisang phetolelo ea metabolism ea cellular37. Haholo-holo e hlophisa ka matla tsoelo-pele ea glucose le glycolysis, e nang le libaka tsa tlama tse nyolohang hoo e batlang e le mefuta eohle ea mefuta e amehang liketsahalong tsena. Liseleng tsa hypoxic, HIF-1 e sebetsa ho thibela sehlahisoa sa glycolysis, pyruvate, ho tlhahiso ea lactate ho fapana le ho fetolela acetyl-CoA le ho kena ka potoloho ea TCA le phosphorylation ea oxidative. Sena se entsoe, bonyane ka karolo, ke HIF-1-up-regulation-expression ea lactate dehydrogenase A (LDH-A), enzyme e arolelanang phetoho ea pyruvate ho lactate, hammoho le pyruvate dehydrogenase kinas ( PDHK), e sebelisang PDH, enzyme e kopanyeletsang phetoho ea pyruvate ho Acetyl Co-A (bona Setšoantšo sa 2). Ho makatsang leha ho le joalo, lisele tse tšoaroang ke orexin li ile tsa bonahala li sutumetsa boholo ba 'mele oa bona oa metabolic ka potoloho ea TCA le phosphorylation ea oxidative 36, e hlahisang tlhahiso e ntlafalitsoeng haholo ea ATP le, mohlomong mohokahanyi e mong oa biosynthetic intermediates mosebeletsi ka ts'ebetso ea litselana tsena. Ha ho tsejoe hore na orexin signaling le hypoxia ka bobeli li ka susumetsa joang ts'ebetso ea HIF-1cy, leha ho le joalo ke karolo e tlase feela ea liphatsa tsa lefutso e atisang ho hlahisoa ka lebaka la hypoxia e kenngoeng liseleng tse tšoaroang ke orexin.

Setšoantšo sa 1 

Kakaretso ea se fumaneng tlhahlobo ea polelo ea mofuta oa phello ea orexin ho lisele tse hlahisang orexin receptor 1. Ka holimo: chate ea pie e akaretsang mesebetsi e hlalositsoeng ea liphatsa tsa lefutso e anngoeng haholo ke ho saena hoa orexin. Ka tlaase: Litsela tse boletsoeng esale pele ...
Feie. 2 

Kakaretso ea litekanyetso tsa phello e kholo ea ho hlalosoa ha orexin ho metabolism ea glucose. OxSig = orexin lets'oao. Molora oa lamunu o emela transporter ea glucose. Metsu e bontša ho hlohlona ha ts'ebetso e bonts'itsoeng 'me mela ea perpendicular e emela ...

Lithuto tse ts'oanang tsa methapo ea hypothalamic e fumanoang ho mofuta oa hlaha kapa mofuta oa OxR1 litheko tse tsoang ka ntle li lumellana le liqeto tsena mme li netefalitse hore litlamorao tse bonoang ke litholoana tsa orexin 36. Ka tsela e itseng, sephetho sena se ipiletsa ka hore se hlalosa tsela eo re utloisisang Biology ea orexin ka eona maemong a mmele. Haeba re lekanya boemo ba ho tsoha le ts'ebetso e phahameng ea "neuronal metabolic", e shebahalang e le taba, hoa utloahala hore sena se ka etsahala ha kelello e hlatsuoa ka tekanyo e tlase ea tsoekere. Ka hona, hoa utloahala hore ho tsoha ho hloka maemo a mangata ka mochine o eketsang katleho ea matla a tsoekere le ho sebetsa. Tlatsetso ea matlafatso ea methapo ea methapo ea kutlo e tla bonahala e tsamaellana le ho shebella tšebeliso ea matla le tšebeliso ea botenya bo matla bo ntšitseng mafura. 8. Leha ho le joalo, ho bohlokoa ho hopola hore thuto ena e ne e tsepamisitse maikutlo ho lisele tse hlalosang mantsoe tsa OxR1 le lisele tsa neuronal tse fumanoeng ho mofuta oa hlaha kapa litoeba tsa OxR1. Ho tsosa le ho hanela botenya bo khothalletsoang ke ho ja, joalo ka ha ho boletsoe ka holimo, joale ho nahanoa hore ke phello ea ho bonts'a molaetsa oa OxR2. E kanna ea ba hore litsela tse bonoang li sebetsa haholoanyane ho putsa boits'oaro le lits'ebetso tse ling tse shebahalang li laoloa ke lets'oao la OxR1-Mediated. Ho tla hlokahala mosebetsi o mongata haholo ka mefuta le lisele tse fapaneng ho rarolla mathata ana. Empa mohopolo oa hore orexin signing ke taolo e kholo ea metabolism ea matla ke mohlala o tsotehang o tla tataisa lithuto tsa nako e tlang.

Na orexin e bonts'a mofets'e?

Ho sibolla hore orexin signaling e khona ho turcha ts'ebeliso ea tsoekere ho bonts'a khokahano e ka eketsang ho eketsoa hoa selekaneng ka ho arola lisele, ka hona, le mofets'e. Leha ho le joalo, liphetho tse phatlalalitsoeng tse boletsoeng ka holimo li bontša hore orexin e ka tsosa metabolism ea matla a oxidative 36, ha lisele tse ngata tsa mofetše li sebelisa glycolysis ea anaerobic bakeng sa bongata ba metabolism ea eona 38. Monyetla o mong ke hore lisele tsa kankere tse sebelisang metabolism ea oxidative li ka sebelisa signation ea orexin ka mokhoa oa autocrine kapa paracrine ho tsosa metabolism ea bona le ho eketseha ha, haeba ho le joalo, li-anteptorists tsa orexin e tla ba likhetho tse khahlisang tsa kalafo. Ka lehlakoreng le leng, haeba orexin e bonts'a matla a metabolic flux ka TCA le oxidative phosphorylation pathways ka litšenyehelo tsa anaerobic glycolysis, joale ts'ebetso ea tsela ena e ka ba chefo ho lisele tsa tumor tse "lemaletseng" mokhoa oa bophelo oa glycolytic.

Ho na le matšoao a karolo ea karolo ea ho saena hoa orexin liseleng tsa mofetše, mme joalo ka ha motho a ka bolela esale pele ho tsoa tlhahlobisong e kaholimo, phello ea ho supa ha orexin e bonahala e fapane ka mefuta e fapaneng ea lisele tsa mofetše. Mohlala, li-orexins li hatella kholo ea lisele ka ho kenya ts'usumetso ea apoptosis ka har'a mofetše oa colon ea motho, lisele tsa neuroblastoma, le lisele tsa "tumor" tsa pancreatic tumor 39. Ka lehlakoreng le leng, polelo ea OxR1 le OxR2 li phahame haholo ho adenomas ho feta cortex e tloaelehileng ea adrenal. Orexin A le B li ka hlohlelletsa ho eketseha ha sele liseleng tsena mme litlamorao tsa phatlalatsoa ka mokhoa o hlakileng ho feta lisele tse tloaelehileng tsa adrenocortical 40. Le ha litlaleho tsena li khahla, kutloisiso ea rona ea bohlokoa ba ho saena ha orexin ka mofets'e, haeba e teng, e sa le lesea mme ho tla hlokahala mosebetsi o mongata ho tseba hore na li-receptor tsa orexin kapa li-activist tse tlase tsa tsela e saenneng li emela lipehelo tse sebetsang bakeng sa kalafo ea chemotherapy. .

Ts'ebetso ea Pharmacological ea Orexin Signaling

Biology e hlahliloeng ka holimo e fana ka maikutlo a hore lingaka tsa maemo a holimo, bahanyetsi le baetsi ba lets'oao la orexin ba ka ba le thahasello e kholo tleliniking. Mohlala, kalafo ea narcolepsy le cataplexy e tlisoang ke ho haella ha tlhahiso ea orexin e lokela ho phekoloa ka ts'ebeliso ea ngaka ea orexin receptor agonist. Ka lehlakoreng le leng, boits'oaro ba bokhoba bo lokela ho phekoleha ka ho sebelisa mohanyetsi oa "orexin receptor antagonist". Lijo tse khothalletsoang-botenya le lefu la tsoekere li ka kopanngoa le "orexin receptor agonist" kapa "allrateic". Likhamphani tse 'maloa tse kholo tsa meriana li entse nts'etsopele ea limolek'hule tse shebileng li-orexin receptors 41.

Li-antagonists tsa Orexin Receptor

Kaha ho tšoaetsoa ha orexin bokong ho etsa hore motho a hlaphoheloe, ho a utloahala hore lithibelo tsa meriana ka tsela ena li ka baka boroko 'me kahoo lihanyetsi tsa orexin receptor e ka ba lithethefatsi tse sebetsang bakeng sa ho phekola boroko. Leha ho le joalo, ntho e tšoenyang haholo e tla ba ho kenyelletsa "cataplexy". Ho joalo, potso ea mantlha e mabapi le nts'etsopele ea litheko tse matla tsa orexin receptor antagonists ke hore na lithibela-mafu tsa nakoana tsa receptor ea orexin li tla baka tšenyo ea narcoleptic le cataplectic phenotype ea orexin e sa foleng.

Lintlha tsa pele ho tsa bongaka le tsa bongaka tse fumanehang ho fihlela joale li re karabo ke "che". Boholo ba data bo tsoa lithutong tsa Almorexant (Setšoantšo sa 3; e tsejwang hape ka hore ke ACT-078573), e ntseng e ntshetswa pele ke Actelion Pharmaceuticals bakeng sa kalafo ya ho hlobaela. Almorexant ke tatrahydroisoquinoline e fumanehang ka molomo eo e ka sebelisang antagonizing ka bobeli ba OxR1 le OxR2. Actelion o phatlalalitse phuputso e entsoeng pele ho 2007 ea pele e tlalehileng kalafo e atlehileng ea rat, lithuto tsa ntja le batho ka Almorexant kapa classical GABA receptor agonist, zolpidem 19. Almorexant o ile a bontšoa a sireletsehile a bile a mamelletse hantle phuputsong ena. E hlahisitse matšoao a bophelo bo botle ba ho robala. Litekong tsa rat, ho bontšitsoe hore Almorexant e hlohlelletsa boroko bo seng ba REM le ba REM. Sena ke sa bohlokoa hobane zolpidem ha e khothalletse boroko ba REM. Habohlokoa, ho ne ho se na matšoao a cataplexy a ileng a bonoa ho efe kapa efe ea liphoofolo tse lekang kapa bakuli ba batho.

Setšoantšo sa 3 

Kakaretso ea nts'etsopele ea Almorexant, mokhethoa oa bongaka bakeng sa kalafo ea ho hloka boroko, le likhakanyo tse amanang le ho ikhetholla ho fapaneng bakeng sa li-receptor tse peli tsa orexin.

Qetellong ea 2009, Actelion o phatlalalitse ho phethoa ha tlhahlobo e batsi ea Phase ea III ea kalafo ea libeke tse peli ea lithuto tsa batho ba baholo le ba baholo ba nang le bothata ba ho hlobaela ba mantlha. Khamphani e re sephetho sa mantlha sa nyeoe, katleho e kholo ea Almorexant holim'a placebo, e ile ea khahlisoa, joalo ka liphihlelo tse 'maloa tsa morao-rao (bona http://www1.actelion.com/en/our-company/news-and-events/index.page?newsId=1365361). Leha ho le joalo, mola o hlakileng oa phatlalatso ea litaba o boletse hore "… ho ile ha etsoa liphuputso tse ling tse tla hloka tlhahlobo le boithuto bo eketsehileng lithutong tsa nako e telele tsa Phase III." Ho tla khahlisa ho tseba hore na sena se bolelang ha data e fumaneha.

Almorexant e bile litholoana tsa lenaneo le leholo la nts'etsopele le qalileng ka tatrahydroisoquinoline 1 (Setšoantšo sa 3) 42. K'homphieutha ena e ile ea hlaha e le ntho ea mantlha e tsoang skrineng e phahameng e sebelisang khalori ea khalori e thehiloeng ho FLIPR liseleng tsa China Hamster Ovary (CHO) tse hlahisang maemo a phahameng a OxR1 ea motho kapa OxR2. Ela hloko taba eo 1 e khetha ka nepo OxR1. Ka nepo, lenaneo lena la kalafo le hlahisitse metsoako e mengata e fapaneng, eo e meng e neng e le bahanyetsi ba babeli ba amohelang ba bang, ha ba bang e ne e le li-inhibitors tse khethiloeng tsa OxR1 kapa OxR2 (bona Setšoantšo sa 3). Ho ile ha bonoa liphetoho tse kholo haholo ka tekanyo ea ho khetha ka lebaka la liphetoho tse fokolang tsa sebopeho. Mohlala, ho nkeloa sebaka ke se seng sa lihlopha tsa "tho "tse holimo ka letsohong le letšo le monko o monate oa 1 e nang le isopropyl ether e hlahisitse mohanyetsi ea khethehileng oa OxR1. Phapang e 'ngoe e khahlisang ke e rarahaneng 3, e khethang OxR2, empa e arolelana likarolo tse ngata tsa sebopeho le mohanyetsi ea kopaneng Almorexant. Ka bomalimabe, ha ho na data ea sebopeho ho li-orexin receptor ka hona motheo oa molek'hule ona ha o tsejoe.

Li-tetrahydroisoquinoline li hole le bo-anteli ba receptor ba orexin ba tlalehiloeng. Mohlala, Actelion e tlalehile li-complex tse arohaneng ka sebopeho joalo ka sulfonamides 4 'me 5, e leng bahanyetsi ba nang le matla a mabeli le OxR2 bahanyetsi ba khethiloeng, ka ho latellana (Setšoantšo sa 4) 43. Ka ho hlahloba meaho, e kenyelletsang konokono ea glycine e fetotsoeng haholo, motho o lekeha ho fihlela qeto ea hore li-tetrahydroisoquinolines le sulfonamides li ka lula libakeng tse fetang holima li-receptor, empa ho latela tsebo ea rona, sena ha se so ka se lekoa.

Setšoantšo sa 4 

Meaho ea lingaka tse ling tsa li-orexin receptor antagonists tse entsoeng ke Actelion Pharmaceuticals.

GSK e tlalehile e ngoe ea lihanyetsi tsa pele tsa orexin receptor, SB-334867 44-46 (Setšoantšo sa 5), komporo e khethang OxR1 ebile e ntse e sebelisoa e le "sesebelisoa" se sebelisoang haholo lithutong tsa ho etsa lipatlisiso tse ithutang biology ea orexin. Ba boetse ba tlaleha mong ka SB-334867 ea lelapa le leng hole, 6, e kenyeletsang unit ea proline, e nang le potency e ntle haholo khahlanong le li-receptor ka bobeli, empa e boloka boikhethelo bo loketseng OxR1 47. Ho nahanoa hore 6 ekaba setho se haufi sa sebopeho sa sebopeho se sa senngoeng seo GSK e ileng ea se etsa liteko tsa bongaka bakeng sa kalafo ea ho hloka boroko e bitsoang SB-674042 41. GSK e phatlalalitse khatelo-pele ea motsoako ona litekong tsa bongaka tsa Phase II ho 2007, empa ha ho na tlhaiso-leseling ea kliniki e seng e fihlile tsebong ea rona.

Sehlopha sa Merck se thehile lira tse khahlanong le li-orexin receptor antagonists 48. Khahlano 7 (Setšoantšo sa 5) e hlahile ho tsoa skrineng e phahameng haholo 'me e netefalitse bokhoni ba vitro potency khahlanong le OxR2 le ts'ebetso e itekanetseng khahlanong le OxR1, empa ho vivo e bonts'itse ts'ebetso e mpe ea mali ea boko. Sena se fumanoe e le sesosa sa hore ke karoloana ea P glycoprotein. Ba fumane hore bothata bona bo ka ntlafatsoa ke methylation ea naetrojene ea benzimidazole 41, 48. Khahlano 8, eo hape e nang le selikalikoe sa phenyl ho fapana le molek'hule o ka har'a "tokelo e kaholimo" ea molek'hule, ke mohanyetsi ea matla oa li-receptor tse peli tse nang le phello e ntle ea khatello ea mali. 8 e bontšitsoe e sebetsa litlamong.

Likhamphani tse ling tsa meriana li hlahisitse likhakanyo tse 'maloa ka ts'ebetso ea in vitro khahlanong le li-orexin receptors, empa tsena li ke ke tsa hlahlojoa mona.

Ho leka ho hakanya hore metsoako e tšoanang e ntseng e etsoa e le lithuso tsa boroko le eona e ka ba molemo bakeng sa kalafo ea lithethefatsi tse sa feleng, leha litlamorao tse totobetseng tsa puso ena ea kalafo e le hore li tla etsa hore lithuto li robale haeba e le bahanyetsi ba li-receptor. Leha ho le joalo, ho sibolloa ha karolo ea ho supa ha orexin ka boits'oaro ba ho lemalla ho atile haholo, mme ho ea ka tsebo ea rona, ha ho liteko tse fumanoeng tsa bongaka tse qalileng li sebelisa metsoako e boletsoeng ka holimo bakeng sa letšoao lena.

Li-Agonists tsa Orexin Receptor le Lits'ireletso

Joalokaha ho boletsoe ka holimo, Yanagisawa le basebetsi-'moho ba fane ka bopaki ba molao-motheo mehlaleng ea liphoofolo hore narcolepsy e ka phekoloa ka moferefere oa orexin receptor agonist 18. Ba sebelisitse peptide e fetotsoeng ea orexin lithutong tsena. Ho makatsang ke hore, ha ho na litsebi tsa kalafo e seng peptide tse seng li tlalehiloe ka har'a lingoliloeng ka tsebo ea rona. Ho thata ho nahana hore likhalase tsa lisebelisoa tse joalo ha li e-so tšoaroe, ka lebaka la palo e pharalletseng ea mosebetsi o etsoang ho bahanyetsi ba li-receptor. Kahoo, ho bonahala ho ka ba bonolo hore ho be thata ho fumana li-agonists tse matla, leha ho sa hlake hore na hobaneng ho le joalo.

Haufinyane tjena, moetsi oa pele ea motle oa tsohle tse amohelang orexin receptor, 9 (Setšoantšo sa 6), o khethiloe. K'hemik'hale ena e fumanoe e tsebahala nakong ea letšolo la ho hlophisa meriana ka mokhoa o itekanetseng o etselitsoeng ho eketsa bokhoni ba mohanyetsi oa phepelo ea orexin receptor. 49. Peptoid 10 e ile ea tsebahatsoa skrineng eo ho eona lisele tse sa sebetseng kapa li sa hlahiseng OxR1, empa li tšoana hantle, li neng li ngotsoe ka dae e mebala e fapaneng (e khubelu le e tala, ka ho latellana) ebe e hokahantsoe le microarray e bonts'a li-peptoids tse likete tse 'maloa tse sa kenngoeng selomong sa khalase. Lisebelisoa tse tlamisang lisele tse hlalosang tsa OxR1 ka mokhoa o khethiloeng li ile tsa khetholloa ke bofubelu bo phahameng: tekanyo e tala ea daese ea fluorescent e hapiloeng sebakeng seo (bona Ref. 50 bakeng sa nts'etsopele ea mokhoa ona). Teko ea sarcosine ea ho lekola 51 e senotse hore ke tse peli feela tsa liketane tse mahlakoreng tse robong tse neng li le ka molek'huleng tse bohlokoa bakeng sa ho tlama lisele tse hlahisang lintho tse amohelang (tse totobalitsoeng ka bofubelu ho Feie. 6). Kameho ea morao-rao le tlhahlobo ea likarolo 11 o netefalitse hore ke "pharmacophore e nyane" bakeng sa ho amohela li-receptor. 11 ke mohanyetsi ea fokolang oa li-receptor tsa orexin ka bobeli le IC50 ea boholo ba 300 μM feela ka vitro.

Setšoantšo sa 6 

Nts'etsopele ea "orexin receptor" Bokaholimo ba peptoid bo ileng ba hlaha e le ntho ea mantlha e tsoang skrineng e tlamang bo bontšoa ka holimo. Karolo ea molek'hule e fumanoeng e le bohlokoa bakeng sa ho tlama li-receptor e totobatsoa ka bofubelu. Sena ...

Sebopeho sa 11 ho ne ho bonahala eka ho fana ka maikutlo a tšoanang le Almorexant (Setšoantšo sa 6) ka hore komporo e ne e na le selikalikoe sa piperonyl se hokelletsoeng setsing sa glycine, athe likarolo tse batlang li tšoana, empa ka selikalikoe sa dimethoxybenyl sebakeng sa piperonyl, li teng Almorexant. U sebelisa mohlala ona e le tataiso, likhatiso tse 'maloa tsa 11 li ile tsa etsoa moo likarolo tsa hydrocarbon li ileng tsa eketsoa ho naetrojene ea amine ka ho fokotsa matla. Mofuta oa benzyl, 12, eo methylene e 'ngoe e neng e kentsoe le eona pakeng tsa selikalikoe se nkhang hamonate le naetrojene e ipakile e le mohanyetsi ea ntlafalitsoeng haholo, leha ho le joalo a ne a e-na le potency e fokolang feela (Feie. 6), ho fana ka maikutlo a hore mohlala o ka nepahala. Lithuto tsa tlholisano ho bona hore na li-peptoid li tsoa ho eng 12 mme Almorexant e qothisana lehlokoa le e mong bakeng sa ho tlama ho receptor ha e so tlaleheloe.

Nakong ea boiteko bo eketsehileng ba ts'ebeliso, komporo 9 e ne e entsoe, e fapaneng le 12 ke feela ka hore selikalikoe sa piperonyl se ile sa buloa likarolo tse peli tsa methoxy le sehokela sa methylene se le seng pakeng tsa glycine nitrogen le reng e nkhang hamonate e neng e le teng ka har'a komporo. 10 ea khutlisoa. Ho makatsang ke hore 9 ha ea ka ea qholotsa OxR1 papisong ea setso sa sele empa e hlahile e eketsa hanyane polelo ea mofuta oa morekisi ea itšetlehileng ka orexin. Litemoso li ile tsa phetoa hape maemong a tlase a orexin (EC20 ea li-hormone) le liphetho li bonts'a hantle hore 9 e na le tšusumetso e ntle ea ts'ebetso ea orexin-Mediated ea receptor. Kopanong ena ea lihormone, 9 e bontšitse EC50 ea boholo ba 120 nM. Ha thupelo eo e ne e etsoa ka mekhahlelo e meholo ea moqapi 9 mme boemo ba orexin bo ne bo emisitsoe, ho fumanoe hore EC50 ea orexin e fokotsehile makhetlo a mane le hore tekanyetso e phahameng ea polelo ea mohatisi e ne e batla e imenne ka makhetlo a mararo ho feta e tlisoang ke maemo a orexin a phetseng hantle. Liphetho tse tšoanang li ile tsa fumanoa litekong tse sebelisang lisele tse bontšang OxR2, ho bonts'a seo 9 ke moetsi oa lintho tse amohelang batho ba babeli.

Ho sibolloa ha moqapi oa li-orexin receptor potentiator ho thabisa haholo mabapi le lits'ebetso tse ka bang teng e le kalafo e khahlanong le botenya / lefu la tsoekere 8, leha ho le joalo ho fihlela joale Ka vivo liteko li tlalehiloe li sebelisa komporo ena. Joalokaha ho boletsoe kaholimo, Yanagisawa o bonts'itse hore "peptide orexin receptor agonist" e emisang peptide e koala botenya bo feteletseng le nts'etsopele ea lefu la tsoekere la mofuta oa II ka litoeba. 8. Kaha liphoofolo tsena, 'me mohlomong, ka lebaka la batho ba fepehileng hantle li ntse li hlahisa litekanyetso tse tloaelehileng tsa lihormone tsa orexin, motho ea nang le tšusumetso e ntle a ka ba molemo ho khothaletsong ketso e ntle ea tlhaho ea lihormone ho batho bana. Ho joalo, moetsi oa tšusumetso ha a na monyetla oa ho ameha kalafo ea narcolepsy, hobane batho ba amehileng ba hlahisa orexin e nyane kapa e se nang eona.

Summary

Joale ho hlakile hore neuropeptide orexin le li-receptor tsa eona tsa kelello li phetha karolo e kholo ho taolong ea ho fepa, ho robala, ts'ebeliso ea matla, ho batla moputso le mekhoa e meng e fapaneng. Hanyane ha ho tsejoe mabapi le liketsahalo tse makatsang tse hlahisitsoeng ke ho saena hoa orexin. Ho na le ts'episo e kholo ea hore litheko tsa meriana tse sebetsanang le litekanyetso tsa meriana li fumaneha ka mokhoa o hlakileng, 'me lik'hamphani tse ngata tsa meriana le li laboratori tsa thuto li na le mananeo a sebetsang sebakeng sena. Le ha ho se na methapo e joalo setsing sa kokelo, mohokahanyi oa lintho tse mpe tse sebelisang orexin receptor antagonist Almorexant o phethile seo ho neng ho bonahala e le teko ea bongaka ea mophato oa boraro e atlehileng bakeng sa kalafo ea ho hloka boroko. Hajoale, ha ho tlaleho ea li-orexin receptor agonists tse tlalehiloeng. Ho bonahala eka ho tla ba le ts'ebetso e ngata sebakeng sena lilemong tse 'maloa tse tlang.

lumela hore baa fokola

Mosebetsi o tsoang laboratoring ea rona e hlalositsoeng tlhahlobisong ena o ne o tšehelitsoe ke chelete ea thuso ea NIH (P01-DK58398) le konteraka e tsoang ho National Heart Lung and Blood Institute (N01-HV-28185).

References

1. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, ​​Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS , Terrett JA, Elshourbagy N, Bergsma ADJ, Yanagisawa M. Cell. 1998; 92 (7): 3-85.
2. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS, 2nd, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG. Proc Natl Acad Sci US A. 1998; 95: 322-327. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
3. Sakurai T, Moriguchi T, Furuya K, Kajiwara N, Nakamura T, Yanagisawa M, Goto K. The Journal of biological chemistry. 1999; 274: 17771-17776. [E fetotsoe]
4. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. Brain Res. 1999; 827: 243-260. [E fetotsoe]
5. Muroya S, Funahashi H, Yamanaka A, Kohno D, Uramura K, Nambu T, Shibahara M, Kuramochi M, Takigawa M, Yanagisawa M, Sakurai T, Shioda S, Yada T. Eur J Neurosci. 2004; 19: 1524-1534. [E fetotsoe]
6. Willie JT, Chemelli RM, Sinton CM, Yanagisawa M. Ann Rev Neurosci. 2001; 24: 429-458. [E fetotsoe]
7. Tsuneki H, Murata S, Anzawa Y, Soeda Y, Tokai E, Wada T, Kimura I, Yanagisawa M, Sakurai T, Sasaoka T. Diabetesologia. 2008; 51: 657-667. [E fetotsoe]
8. Funato H, Tsai AL, Willie JT, Kisanuki Y, Williams SC, Sakurai T, Yanagisawa M. Cell metabolism. 2009; 9: 64-76. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
9. Chemeilli R, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Clay Williams S, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M. Cell. 1999; 98: 437-451. [E fetotsoe]
10. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. Cell. 1999; 98: 365-376. [E fetotsoe]
11. Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, Sanghani S, Traskman-Bendz L, Goddard AW, Brundin L, Shekhar A. Bongaka ba Tlhaho. 2009; 16: 111-115. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
12. Hollander JA, Lu Q, Cameron MD, Kamenecka TM, Kenny PJ. Proc Natl Acad Sci US A. 2008; 105: 19480-19485. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
13. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Mahlale. 2009
14. Moriguchi T, Sakurai T, Nambu T, Yanagisawa M, mangolo a Goto K. Neuroscience. 1999; 264: 101-104. [E fetotsoe]
15. Yamanaka AB, Willie CT, Hara JT, Tsujino J, Mieda N, Tominaga M, Yagami M, Sugiyama K, Goto F, Yanagisawa K, Sakurai MT. Neuron. 2003; 38: 701-713. [E fetotsoe]
16. Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, Kawashima M, Mayer G, Plazzi G, Nevsimalova S, Bourgin P, Hong SS, Honda Y, Honda M, Hogl B, Longstreth WT, Jr, Montplaisir J, Kemlink D, Einen M, Chen J, Musone SL, Akana M, Miyagawa T, Duan J, Desautels A, Erhardt C, Hesla PE, Poli F, Frauscher B, Jeong JH, Lee SP, Ton TG, Kvale M, Kolesar L , Dobrovolna M, Nepom GT, Salomon D, Wichmann HE, Rouleau GA, Gieger C, Levinson DF, Gejman PV, Meitinger T, Young T, Peppard P, Tokunaga K, Kwok PY, Risch N, Mignot E. Natural genetics. 2009 [Tlhahiso ea mahala ea PMC] [E fetotsoe]
17. Nishino S, Okura M, Mignot E. Ho robala Med Rev. 2000; 4: 57-99. [E fetotsoe]
18. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Proc Natl Acad Sci US A. 2004; 101: 4649-4654. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
19. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu C, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F. Moriana oa tlhaho. 2007; 13: 150-155. [E fetotsoe]
20. Grey MA, Critchley HD. Neuron. 2007; 54: 183-186. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
21. Naqvi NH, Rudrauf D, Damasio H, Bechara A. Science. 2007; 315: 531-534. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
22. Wang Z, Tumelo M, Patterson F, Tang K, Kerrin K, Wileyto EP, Detre JA, Lerman C. J Neurosci. 2007; 27: 14035-14040. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
23. Harris GC, Wimmer M, tlhaho ea Aston-Jones G.. 2005; 437: 556-559. [E fetotsoe]
24. Kenny PJ. Mekhoa litabeng tsa saense ea meriana. 2007; 28: 135-141. [E fetotsoe]
25. Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ, Yanagisawa M, Nestler EJ, DiLeone RJ. J Neurosci. 2003; 23: 3106-3111. [E fetotsoe]
26. Nishino S. Robala Med. 2007; 8: 373-399. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
27. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, Sakurai T. Neuron. 2001; 30: 345-354. [E fetotsoe]
28. Yu X, Park BH, Wang MO, Wang ZV, Unger RH. Proc Natl Acad Sci US A. 2008; 105: 14070-14075. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
29. Oral EA, Ruiz E, Andewelt A, Sebring N, Wagner AJ, Depaoli AM, Gorden P. J Clin Endocrinol Metab. 2002; 87: 3110-3117. [E fetotsoe]
30. Heinonen MV, Purhonen AK, Makela KA, Herzig KH. Acta Physiol (Oxf) 2008; 192: 471-485. [E fetotsoe]
31. Silveyra P, Catalano PN, Lux-Lantos V, Libertun C. Am J Physiol Endocrinol Metab. 2007; 292: E820-828. [E fetotsoe]
32. Silveyra P, Lux-Lantos V, Libertun C. Am J Physiol Endocrinol Metab. 2007; 293: E977-985. [E fetotsoe]
33. Johren O, Neidert SJ, Kummer M, Dendorfer A, Dominiak P. Endocrinology. 2001; 142: 3324-3331. [E fetotsoe]
34. Adeghate E, Fernandez-Cabezudo M, Hameed R, El-Hasasna H, El Wasila M, Abbas T, Al-Ramadi B. PLoS One. 2010; 5: e8587. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
35. Ekholm ME, Johansson L, Kukkonen JP. Khokahanyo ea lipatlisiso tsa biochemical le biophysical. 2007; 353: 475-480. [E fetotsoe]
36. Sikder D, Kodadek T. Genes & Dev. 2007; 21: 2995-3005. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
37. Kaelin WGJ. Biochem Biophys Res Comm. 2005; 338: 627-638. [E fetotsoe]
38. Vander Heiden MG, Cantley LC, Thompson CB. Mahlale. 2009; 324: 1029-1033. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
39. Rouet-Benzineb P, Rouyer-Fessard C, Jarry A, Avondo V, Pouzet C, Yanagisawa M, Laboisse C, Laburthe M, Voisin T. The Journal of chemistry ea biology. 2004; 279: 45875-45886. [E fetotsoe]
40. Spinazzi R, Rucinski M, Neri G, khalendara ea LK, Nussdorfer GG. J Clin Endocrinol Metab. 2005; 90: 3544-3549. [E fetotsoe]
41. Roecker AJ, Coleman PJ. Khemo ea holimo ea Chem. 2008; 8: 977-987. [E fetotsoe]
42. Koberstein R, Aissaoui H, Bur D, Clozel M, Fischli W, Jenck F, Mueller C, Nayler O, Sifferlen T, Treiber A, Weller T. Chimia. 2003; 57: 270-275.
43. Aissaoui H, Koberstein R, Zumbrunn C, Gatfield J, Brisbare-Roch C, Jenck F, Treiber A, Boss C. Litlhaku tsa likokoana-hloko le tsa bongaka. 2008; 18: 5729-5733. [E fetotsoe]
44. Porter RA, Chan WN, Coulton S, Johns A, Hadley MS, Widdowson K, Jerman JC, Brough SJ, Coldwell M, Smart D, Jewitt F, Jeffrey P, Austin N. Bioorganic & meriana ea k'hemistri ea bongaka. 2001; 11: 1907-1910. [E fetotsoe]
45. Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA, Jerman JC. Br J Pharmacol. 2001; 132: 1179-1182. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
46. Rodgers RJ, Halford JC, Nunes de Souza RL, Canto de Souza AL, Piper DC, Arch JR, Upton N, Porter RA, Johns A, Blundell JE. Eur J Neurosci. 2001; 13: 1444-1452. [E fetotsoe]
47. Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ. Br J Pharmacol. 2004; 141: 340-346. [Tlhahiso ea mahala ea PMC] [E fetotsoe]
48. Bergman JM, Roecker AJ, Mercer SP, Bednar RA, Reiss DR, Thekollo RW, Meacham Harrell C, Pettibone DJ, Lemaire W, Murphy KL, Li C, Prueksaritanont T, Winrow CJ, Renger JJ, Koblan KS, Hartman GD , Coleman PJ. Litlhaku tsa likhemik'hale le tsa bongaka. 2008; 18: 1425-1430. [E fetotsoe]
49. Lee J, Kodadek T. Chem Sci. 2010; 1 doi: 10.1039 / C0SC00197J. Ka ho tobetsa. [Tlhahiso ea mahala ea PMC] [E fetotsoe] [Ref Ref Cross]
50. Udugamasooriya DG, Dineen SP, Brekken RA, Kodadek T. J Amer Chem Soc. 2008; 130: 5744-5752. [E fetotsoe]
51. Lim HS, Archer CT, Kim YC, Hutchens T, Kodadek T. Chem Comm. 2008: 1064-1066. [E fetotsoe]